JOAN SHEPHERD: Open Payments
NPI 1689838294 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,759 in 80 payments from 16 companies in 2025. Trend: 2023 $29 · 2024 $766 · 2025 $1,759
Food & beverage: $1,759
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $370 |
| Vanda Pharmaceuticals Inc. | 16 | $326 |
| ABBVIE INC. | 14 | $206 |
| Alkermes, Inc. | 11 | $196 |
| Axsome Therapeutics, Inc. | 4 | $173 |
| E.R. Squibb & Sons, L.L.C. | 5 | $162 |
| Otsuka America Pharmaceutical, Inc. | 7 | $133 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $33 |
| TMS NeuroHealth Centers Inc. | 2 | $25 |
Products named: CAPLYTA, FANAPT, VRAYLAR, ARISTADA, Auvelity, COBENFY, REXULTI, ABILIFY ASIMTUFII.
Industry payments across VA — which companies pay providers there.
